Pontifax Management 4 G.P. (2015) Ltd.

10% owner Pontifax Management sells entire 4.79M share position for $85.0M at $17.75; stock now $13.83, -80.2% from high.

Pontifax Management 4 G.P. (2015) Ltd., a 10% shareholder in Keros Therapeutics, executed 4 separate sales on 2025-10-15 totaling 4,787,331 shares for $84,975,125.25, liquidating its entire holdings at $17.75 per share. The company's current stock price of $13.83 represents a significant decline from the sale price, and the stock trades -80.2% from its 52-week high of $70.00, suggesting material deterioration in investor sentiment since the peak. Keros is operating at substantial losses with net income of $-30,696,000.00 against revenue of $18,168,000.00 in the latest quarter, despite explosive revenue growth of +2251.0% year-over-year. The complete exit by a 10% institutional holder is a material capital event that removes meaningful anchor ownership and raises questions about the major shareholder's confidence trajectory relative to the company's profitability trajectory.

10% Owner Pontifax Management buys 1,000,000 shares (1.00M) of LBRX at $15.00 in $15.0M transaction; 3 other insiders also bought within 14 days

Pontifax Management 4 G.P. (2015) Ltd., a 10% owner, purchased 1,000,000 shares of LB Pharmaceuticals at $15.00 per share for a total value of $15,000,000.00, increasing its holdings from 411,681 shares to 1,411,681 shares (+242.9%). This purchase is notable because it represents a substantial commitment of capital by a significant stakeholder immediately following the company's recent listing (4 trading days ago). The transaction occurred alongside a cluster pattern: 3 other insiders also bought within the past 14 days. This synchronized insider accumulation at the company's early post-IPO stage, combined with the magnitude of the principal owner's stake increase, suggests broad internal alignment on valuation shortly after public market entry.